References
- Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348:69-74; PMID:25838375; http://dx.doi.org/10.1126/science.aaa4971
- Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med 2013; 19:747-52; PMID:23644516; http://dx.doi.org/10.1038/nm.3161
- Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014; 344:641-5; PMID:24812403; http://dx.doi.org/10.1126/science.1251102
- Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky VV, Parkhurst MR, Ankri C, Prickett TD, Crystal JS et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin. Invest 2015; 125:3981-91; PMID:26389673; http://dx.doi.org/doi: 10.1172/JCI82416
- Desai DV, Kulkarni-Kale U. T-cell epitope prediction methods: an overview. Methods Mol Biol 2014; 1184:333-64; PMID:25048134; http://dx.doi.org/10.1007/978-1-4939-1115-8_19
- Rodenko B, Toebes M, Hadrup SR, van Esch WJ, Molenaar AM, Schumacher TN, Ovaa H. Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc 2006; 1: 1120-32; PMID:17406393; http://dx.doi.org/10.1038/nprot.2006.121
- Leisegang M, Kammertoens T, Uckert W, Blankenstein T. Targeting human melanoma neoantigens by T cell receptor gene therapy. J Clin. Invest 2016; 126:854-8; PMID:26808500; http://dx.doi.org/10.1172/JCI83465
- Kalaora S, Barnea E, Merhavi-Shoham E, Qutob N, Teer JK, Shimony N, Schachter J, Rosenberg SA, Besser MJ, Admon A et al. Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. Oncotarget 2016; PMID:26819371; http://dx.doi.org/10.18632/oncotarget.6960
- Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 348:124-8; PMID:25428507; http://dx.doi.org/10.1038/nature13988
- Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348:124-8; PMID:25765070; http://dx.doi.org/10.1126/science.aaa1348